All
Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset
The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.
Ovarian Cancer Teaches Hard Life Lessons
Having a life-threatening disease reminds me daily to make the most of whatever time I have.
A Cancer Institution is Seeking to Address Food Insecurity in Patients With Cancer
Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood cancers undergoing treatment.
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC
The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.
Brukinsa May Improve Efficacy Versus Imbruvica in R/R CLL and SLL
Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.
Life After MDS and Accomplishing Your Goals
After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.
Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.
An Expert Shares Her Advice For Managing Side Effects in Cervical Cancer
Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cervical cancer who are experiencing side effects.
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.
Palliative Care May Improve Quality of Life in Esophageal Cancer
End-of-life palliative care consultations may also ease financial strain for patients with esophageal cancer.
Understanding Food Insecurity and Malnutrition During Cancer Treatment
Dr. Anna Arthur discusses how the NOURISH trial is addressing food insecurity and malnutrition in patients undergoing treatment for their blood cancers.
When A Spouse Dies from Cholangiocarcinoma: Praise for Single Parents
Despite the initial shock and challenges, I found strength and support within the community of single parents.
Oral Liporaxel May Be Superior To Intravenous in Advanced Gastric Cancer
Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.
How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.
Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC
Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.
The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.
Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer
Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.
ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer
Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.
Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs
Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.
CRT and Chemo May Not Improve Survival in Resected Gallbladder Cancer
Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve relapse-free survival.
Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC
Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.
Aspirin May Reduce Recurrence in PI3K-mutated Colorectal Cancer
Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.
Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract
A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.
Bezuclastinib Plus Sutent May Be Safe and Effective in GIST
Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.
When Cancer Is Not the Only Thing Going On
My journey as a foster parent paralleled my cancer experience, both demanding resilience, support, and a redefinition of normal.
Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis
Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.
Whitesnake Guitarist John Sykes Died of Cancer, Mike Peters Starting CAR-T
From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.
Opdivo Regimen May Prolong Survival in Chinese Patients With Certain GI Cancers
Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction or esophageal cancer.
